UNSPSC 51282901: Cinoxacin

This classification denotes a quinolone antibiotic with the molecular formula C12H10N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LMK22VUH23, chemically known as 1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylic acid but generally known as cinoxacin, which bears US NIH Compound Identifier 2762. European Medicines Agency schedules Cinoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06309MIG.

UNSPSC 51282901 Cinoxacin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity explicitly tagged to this code—Seminole County, Florida's IFB60459723LAS for Naloxone and drug deactivation systems—involves naloxone and harm-reduction equipment, not cinoxacin, a fluoroquinolone antibiotic. The three other opportunities posted between January and June 2026 (Texas HHS's RFI on direct-to-manufacturer prescriptions, the City of Tampa's IFB for medical and first aid supplies, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products) address pharmaceutical procurement at scale but do not reference cinoxacin or fluoroquinolone antibiotics by name. State and local jurisdictions procure pharmaceuticals through established cooperative purchasing vehicles and manufacturer-wholesaler networks, yet cinoxacin does not appear as a line item in any of these recent competitive solicitations.

The geographic spread of related pharmaceutical procurement spans Florida, Texas, and Minnesota-led multistate activity, but no issuing body has posted a dedicated solicitation for cinoxacin or identified it as a requirement in their recent RFPs, RFQs, IFBs, or ITBs. Buyers acquiring specialty pharmaceuticals typically consolidate demand through cooperative agreements with established wholesalers or directly through state health departments and county health services. The absence of cinoxacin from recent state and local notices—despite the presence of broader pharmaceutical and medical-supply procurement—suggests either limited current demand at the state and local level, procurement through standing agreements or scheduled renewals not currently in open competition, or vendor positioning under higher-tier pharmaceutical family codes rather than this specific commodity code. Firms pursuing state and local pharmaceutical opportunities should monitor MMCAP and state health department RFPs, but this particular code shows no active market signal at present.